Saxenda (Liraglutide 3 mg) by Novo Nordisk is a pharmaceutical-grade GLP-1 receptor agonist delivered via a pre-filled injectable pen, indicated for the clinical management of obesity and overweight conditions associated with weight-related comorbidities in adult patients. Each box contains 3 pens. Liraglutide is a well-established compound with an extensive clinical research history in metabolic and endocrinological medicine.
✔ Key Research Insights
- Studied for its role in mimicking endogenous GLP-1 activity, with documented effects on appetite regulation and caloric intake reduction in research subjects
- Investigated for its efficacy in producing clinically significant weight reduction when administered alongside lifestyle modification protocols in clinical trials
- Researched for its influence on obesity-related comorbidity risk reduction, including parameters associated with type 2 diabetes incidence and cardiovascular risk markers in documented subject populations
- Examined for its effects on quality of life indices, mobility parameters, and metabolic health outcomes in clinical observations
- Documented as an established GLP-1 receptor agonist with an extensive safety and efficacy profile across international clinical trial literature
📦 Product Specifications
- Manufacturer: Novo Nordisk
- Product: Saxenda
- Molecule: Liraglutide
- Concentration: 3 mg
- Form: Pre-filled injectable pen (subcutaneous)
- Volume: 3 pens per box
- Clinical reference: dosage should be determined by a qualified healthcare professional
⚙ How It Works
Liraglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist that mimics the action of endogenous GLP-1, a hormone involved in appetite regulation and caloric intake modulation. Following subcutaneous administration in research subjects, liraglutide binds to GLP-1 receptors in the hypothalamus and gastrointestinal tract, producing documented effects on satiety signaling and gastric emptying rate. These mechanisms are associated in clinical literature with reduced appetite and decreased food consumption, contributing to a sustained caloric deficit in study populations. Clinical trials have documented statistically significant weight reduction outcomes when liraglutide administration is combined with structured dietary and lifestyle modification protocols. The compound's effects on insulin secretion and glucagon suppression have also been subjects of research interest in the context of metabolic comorbidity management.
⭐ Product Overview
- Manufactured by Novo Nordisk, a globally recognized pharmaceutical company with an established presence in metabolic and endocrinological medicine
- Pre-filled pen delivery system supporting precise and consistent subcutaneous dosing per administration
- Established GLP-1 receptor agonist with one of the most extensively documented clinical profiles in obesity pharmacotherapy
- Indicated for use in combination with lifestyle modification protocols, as referenced across international obesity management guidelines
- Widely recognized under the Saxenda and liraglutide designations in clinical and regulatory literature worldwide
Saxenda 3 pen in Box / Liraglutide Thailand
The dosage and administration of Saxenda typically follow a gradual titration schedule to minimize side effects. Here's a general guideline for using Saxenda:
- Starting Dose: Saxenda is typically initiated at a low dose to minimize gastrointestinal side effects. The recommended starting dose is 0.6 mg once daily.
- Titration: Over a few days or weeks, the dosage is gradually increased. It's often increased by 0.6 mg per day at weekly intervals until reaching the recommended maintenance dose.
- Maintenance Dose: The maintenance dose of Saxenda is 3 mg once daily. This is the dosage that's typically effective for weight management.
- Injection Site: Saxenda is injected subcutaneously (under the skin) into the abdomen, thigh, or upper arm. The injection site should be rotated daily to minimize the risk of skin reactions.
